Elan submits MS data for trial drug Antegren

Irish pharmaceutical firm Elan and partner Biogen announced today that they have submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the approval of Antegren for the treatment of multiple sclerosis (MS).

The submission includes one-year data from two ongoing Phase III trials, part of a two-year trial period that both companies have committed to.